Invent: Life Sciences

Calling all Invent: Life Sciences Subscribers! While you wait for more episodes, make sure to subscribe to our sister podcast, Invent: Health, which has just begun its second season. Listen to the trailer here now! Invent: Health sees host Matt Parker explore the fascinating future of Health technologies. From new closed-loop systems for diabetes to sensing innovations in cardiac health, Matt will be taking a look behind the scenes of these technologies and meeting the people working to transform our collective health.Listen and subscribe from anywhere you get your podcasts, just search 'Invent: Health'. You can also follow the Invent: Health series from our Transistor page and listen to the recent episode on the future of epilepsy treatment: inventhealth.transistor.fm The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: www.ttp.com

The pandemic drastically altered the landscape for investment flowing into the Life Sciences. Not only was there more money going in, but the market needs changed too, with an unprecedented focus on scaling sectors like testing and vaccines. But what did this mean for sectors which were not on the Covid front line? What happened to the trends that were in train before the pandemic hit? And what have we learnt from this experience that we can deploy in the face of the next global challenge? In this episode of Invent: Life Sciences, we look at the past, present and future of investing in the sector, to explore the profound effects that the pandemic has had on it as a whole - and find that, when we pull together, amazing things can happen.Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsDr. Gonzalo GarciaGonzalo Garcia is a Biotech investor, company builder and partner at Syncona limited. Syncona are a company who found, build and fund early stage companies to turn science into transformational treatments, in fields ranging from cell and gene, to biologics and small molecule. Prior to this, Gonzalo completed a PhD in Protein Biophysics from the University of Cambridge, an EMBO Short Term Fellowship in Cell Biology at Harvard Medical School, and was a project leader at Boston Consulting Group. His work at Syncona includes his role as Chief of Staff and Board observer at Resolution Therapeutics.https://www.linkedin.com/in/gonzaloagarciag/?originalSubdomain=ukDr. Jason MelladJason Mellad is the CEO and co-founder of Start Codon. After a phd in medicine from the University of Cambridge, Jason worked in various directing roles for a number of exciting Life Sciences companies, like Cambridge Epigenetics, before founding Start Codon in late 2018. Start Codon are a venture capital investor and venture builder who support aspiring entrepreneurs in development and commercialisation of their businesses. They look for the most disruptive innovations in the life sciences space, and have already seen dozens of successful start ups come through their programme to bring their ideas to the world.https://www.linkedin.com/in/jason-mellad-54890622/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

In the past decade, two events have sent shockwaves through the diagnostics industry: Theranos and Covid. The first, is a parable against faking it in an industry which rightly prizes accuracy and safety. The second was an almost insatiable demand for diagnostic testing kits, where the speed of information took second place to accuracy. Was Elizabeth Holmes onto something when she founded Theranos? What if her devices had been able to live up to the hype? And what reputation does self-testing now have in the diagnostics industry? In this episode of Invent Life Sciences, we take a look at the Theranos story and the Covid pandemic and see what lessons can be learned from each. Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsProfessor Tony CassTony is a professor of chemical biology at Imperial College London, an institution he has been a part of for the best part of three decades. Alongside his fellowship of the Royal Society of Chemistry, Tony pioneered the use of synthetic electron transfer mediators for enzyme biosensors, and his work in this area led to the development of the first electronic blood glucose measuring system. https://www.linkedin.com/in/tonycass/?originalSubdomain=ukDr. Giles SandersGiles is the head of In Vitro diagnostics at TTP and has been with us for two decades. During that time he has been influential in the development of numerous diagnostics systems that have been successfully placed on the market. He works across all aspects of In Vitro diagnostics, from automated central lab, to point of care and home use devices. https://www.linkedin.com/in/gilessanders/?originalSubdomain=ukThe Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

Following our first episode of two focusing on cell and gene therapies, outlining the promise and practicalities of delivering curative therapies for chronic diseases, we now focus on cell therapies - so called ‘living drugs' that are both as powerful as they are complex. Despite the impressive trials and life-changing impacts at the individual level, it's still not possible to manufacture cell therapies at scales that could benefit a wider range of patients. So what are the differences between cell therapies and conventional medicines that make them so difficult to manufacture? Can we redeploy hardware and learnings from other industries or are custom solutions needed? And does the ‘where' we manufacture these therapies matter more than the ‘how'? As we discover in this episode, efforts to address these questions and provide scalable manufacturing solutions could unleash a new wave of pharmaceutical innovation that promises to revolutionise the way we develop medicines. Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsDr. Edwin StoneEd is our head of cell and gene at TTP. After a PHD specialising in Vehicle Dynamics from the University of Cambridge, Ed started working at TTP some 18 years ago, most of which has been spent specialising in cell and gene. He's been focusing on the manufacturing realm of cell and gene for the past seven years. His work spans everything from commercial strategy through to technology development and on to production.https://www.linkedin.com/in/edwin-stone-98560212/Mike LehmickeMike is the Senior Director of Science and Industry Affairs at the Alliance for Regenerative Medicine, and has over 20 years of R&D experience in biomaterials, medical devices, and regenerative medicine. His work focuses on cell based tissue engineering, bioceramics and medicines which have the ability to help repair or replace damaged human cells or tissues.https://www.linkedin.com/in/michael-lehmicke-76b45435/Dr. Félix A. Montero-JulianFélix is a Scientific Director of the Healthcare Business of bioMérieux. With over 25 years of experience in industrial and clinical diagnostics, Félix is extensively involved in the implementation and acceptance of rapid and alternative microbiological methods, with an array of technical experience across the cell and gene therapy manufacturing process.https://www.linkedin.com/in/f%C3%A9lix-a-montero-julian-phd-0a3a501b/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

With therapies like cell and gene - amongst some of the most significant innovations in modern medicine - the idea of delivering cures for conditions from cancer to diabetes is now within the realm of scientific possibility. But will it be possible to provide the benefits of advanced therapies to all? Should we expect our healthcare systems to foot the bill? And can we re-imagine the development ecosystem to truly realise the potential of cell and gene therapies? In this first of two episodes about curing diseases and cell & gene therapies, we outline why we would want to treat diseases in this way, the main economic barriers to achieving it, and where these exciting new therapies are going next.Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsDr. Dan StrangeDan is a technologist and engineering leader with a background in tissue biomechanics, regenerative medicine, and mechanical engineering. He's been at TTP for the past decade, driving forward large development programs from start to finish, as well as being a huge advocate for cell and gene therapies.https://www.linkedin.com/in/drdanstrange/Professor Jacob PetersenJacob is the head of cell therapy research & development at Novo Nordisk and an adjunct professor in biomedicine at Copenhagen University Medical Faculty. With over 20 years in the pharmaceutical and biotechnology spaces, Jacob has worked in R&D for everything from diabetes to cardiovascular disease, and through his current head of cell therapy R&D role, he is involved in the creation of new treatments in this space from start to finish. https://www.linkedin.com/in/jacob-petersen-820529/Dr. Kath MackayKath is the director of Life Sciences for Bruntwood SciTech, a company that provides companies with the infrastructure around Cell and Gene. Previously on the executive management team at Innovate UK, Kath has a track record which proves her passion for growing the UK's life sciences sector, and in her new role is responsible for developing Bruntwood SciTech's life sciences vision, strategy and services in their campuses, which includes Alderley Park, Birmingham Health Innovation Campus, Citylabs, Manchester and Melbourn Science Park.https://www.linkedin.com/in/drkathmackay/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

From cosmetics to medicines, animal testing is still widely mandated by regulators. Up to now, there have been few other ways to gather information about the potential human response to drug candidates. But are animal models still the most effective way to test drugs before we use them in humans? Or are these in vivo models outdated, ready to be replaced by innovative new in vitro models of drug development? In this episode of TTP Invent: Life Sciences, we take a look at some of the fascinating alternatives to animal testing in drug development, before assessing what new realms of medicine these new methods could soon open up - from replicating your organs on a chip, to regenerating entire tissues.Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsProfessor Molly Stevens FRS FRENGMolly is Professor of Biomedical Materials and Regenerative Medicine in the Departments of Materials and Bioengineering at Imperial College London. Following a postdoc working on tissue engineering methods with Bob Langer at MIT, Molly set up her own group at Imperial in 2004. The Stevens Group is a multidisciplinary research group using innovative bioengineering approaches to address key problems in regenerative medicine and biosensing.https://www.linkedin.com/in/molly-stevens-81742822/Dr. Lorna EwartLorna is the CSO at Emulate, a company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Lorna is passionate about the pursuit of drug discovery and development. After working in the Microphysiological Systems Centre of Excellence within AstraZeneca, and beginning her own firm Veroli Consulting, Lorna is now renowned for her expertise in Organ-Chips and Organoids.https://www.linkedin.com/in/lornaewart/Professor Maria KavallarisMaria is best known for her pioneering work in children's cancer. Last year she and collaborator Justin Gooding were awarded the Australian Museum Eureka Prizes for their contribution to a 3D bioprinting technology that promises to revolutionise cancer research, and her work on tumour cells, drug resistance, nanotechnologies and bioprinting have produced countless new discoveries to the field.https://www.linkedin.com/in/mariakavallaris/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

The hunt to discover new pharmaceuticals in areas of high unmet need can be complex, time-consuming, and costly. For every life saving therapy that hits the market, thousands and even millions of candidate drugs are rejected. A new technology could be changing the way we home in on the most effective therapy: AI. The use of AI in drug discovery - whether through mining research or in highlighting new experimental insight - is one of the most exciting new sectors in the field. But how does it really work? What are the conditions needed to implement it? Is it really anything more than just a useful tool? In this episode of Invent: Life Sciences from TTP, we take a look at this fascinating new frontier for drug discovery.Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsDr. Sarah MorrowSarah is a Life Sciences Consultant at TTP, joining in 2020 after getting her PhD specialising in Organic Chemistry from the University of Oxford. Sarah brings a chemist's perspective on the challenges encountered within drug discovery, as well as focusing on the technology - both hardware and software - that could enable and accelerate the field.https://www.linkedin.com/in/sarah-morrow-841719146/Aaron MorrisAaron Morris is the CEO and co-founder of PostEra, a company building an end-to-end medicinal chemistry platform to advance drug discovery, using machine learning and AI to do so. After seeing the limiting nature of drug discovery on bio tech companies and pharma, Aaron set up PostEra to come in at this early stage and work alongside them to reduce these issues, and to serve the world's ever expanding community of drug hunters.https://postera.ai/Dr. Andreas BenderAndreas Bender is a Professor of Life Sciences informatics interested in developing new life science data analysis methods for their application in drug discovery. After over a decade at Cambridge University working in molecular informatics, Andreas is now the CSO at Terra Lumina, a company building the world's largest dataset of natural compounds, using AI that unlocks the connection between nature's small molecules and the human body.https://terralumina.bio/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

What is the potential of synthetic biology? A chance to create life-changing therapies by speaking cells' very own language? Or could rogue researchers use it to turn our own biology against us?Since synthetic biology emerged as a field, the aspirations for its benefits have been as speculative as the concerns about its misuse, making one of the most fascinating and divisive fields in life sciences. But what are its real applications today? And where is it going next? In this episode of Invent: Life Sciences we break down the history of this field, focusing in how breakthroughs in our understanding of DNA allowed it to flourish, before assessing whether its applications today will live up to its incredible potential.Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsDr. Michael ChenMichael is the CEO and founder of synthetic biology startup Nuclera. With a PHD in Chemistry from the University of Cambridge, Michael has ten years experience in scientific research, from nucleic acid chemistry to protein expression and crystallography, resulting in twelve published papers. Nuclera is the outcome of this work - it's a company whose fundamental goal is to make biology accessible, through their groundbreaking desktop bioprinter, which combines eProtein synthesis and eDrop digital microfluidics, to enable protein printing within 24 hours.https://www.nuclera.com/Dr. Gary M. SkinnerGary is a consultant in applied biophysics at TTP, and his research focuses on various fields within the syn bio space. In his career, Gary has worked everywhere from York to Arizona to the Netherlands on projects as far afield as using optical tweezers to observe initiation of transcription of DNA, to applying super-resolution imaging technology to DNA sequencing.https://www.linkedin.com/in/gmskinnerbioscience/Professor Tom EllisTom is a Professor of Synthetic Genome Engineering at Imperial College London. He currently leads a research team in synthetic genome engineering and synthetic biology in the Department of Bioengineering. His research, for which he has one multiple awards, focuses on developing the foundational tools for accelerating, automating and scaling design-led synthetic genomics and synthetic biology.https://www.linkedin.com/in/tomellisphd/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

When the first human genome was sequenced, the whole project was estimated to have cost some 3 billion dollars and took over 13 years. Now, with massively parallel Next Generation Sequencing it is possible to sequence the human genome in less than 24 hours at a cost of under $1,000. With a rapid decline in sequencing costs, both the number of applications and the amount of data produced have boomed, driving a revolution in medicine. However, with the advent of new enabling technologies, what is next? What are the new and exciting technologies in the sequencing space which will be truly disruptive in the future? And what technical innovation is required to bring these technologies to the mainstream user or even the clinic?In this episode of Invent: Life Sciences, we explore the race to innovate in the sequencing arena, what's happened so far, and what's going to happen next.Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsDr. Geoff Smith Geoff is a next generation sequencing pioneer who has built and led many of the teams that invented and developed the entire NGS workflow - from sample prep, to the core sequencing technology, to new instrument systems. Previously Ilumina's global head of ​​technology development, he is now an independent board member of various exciting start ups.https://www.linkedin.com/in/geoff-smith-328b5b9/Dr. Lauren LaingLauren leads the 'Omics Team at TTP – a team addressing current needs in DNA and RNA sequencing and also looking to develop tools for future multi- proteo- and other ‘omic workflows. Prior to this Lauren has worked in developing new sequencing technologies, novel chemistries, approaches to automating sample preparation, and research applying sequencing in single cell and epigenetic applications.https://www.linkedin.com/in/epigenomicslvl/  Dr. James HadfieldJames is the Senior Director of Oncology Translational Medicine at AstraZeneca and author of the CoreGenomics blog, enseqlopedia. A life-sciences researcher and senior operational manager with over 20 years' experience in Genomics technologies, James is a thought leader in genomics with a broad network across academia and industry.http://enseqlopedia.com/coregenomicsThe Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

Following our thrilling first series of Invent all about health technology, the team at TTP are back with a new series all about the Life Sciences, to explore the impact of biology and technology on the life sciences sector.Life sciences are often referred to as the Fourth Industrial Revolution, deploying biology and technology in real-world applications to transform medicine, diagnostics, and ultimately our ability to engineer the building blocks of life itself. From delivering cures using cell therapies to harnessing the genetic code, from learning from the Theranos scandal to understanding disruption in drug discovery, Invent: Life Sciences will take a deep dive into the most exciting developments in the field.The new series begins May 31st - see you then!

We're currently taking a short hiatus after our first season, where we covered everything from curing blindness to controlling pain; from making hospitals more sustainable to putting a hospital in your home. Before we come back with season two, our friends over at the Life Sciences team here at TTP are going to be dropping their very own series in the new year. Invent: Life Sciences will be a series looking at all things biology - the efficacy of animal testing, the benefits of synthetic biology, even asking what the infamous team behind Theranos actually got right in terms of diagnostics. But in the meantime, we wanted to give you some bonus content to whet your appetite for things to come and spread a bit of Christmas cheer. So here's the full conversation from one of our favourite interviews of this series. In early November, we spoke with Dr. Pearse Keane for our episode on eyecare, looking at how the world's top doctors and scientists are working to find ways to restore sight.Dr. Pearse Keane is a consultant ophthalmologist at Moorfields Eye Hospital, London, and an associate professor at UCL Institute of Ophthalmology. In 2016, he initiated a formal collaboration between Moorfields Eye Hospital and Google DeepMind, with the aim of developing artificial intelligence (AI) algorithms for the earlier detection and treatment of retinal disease. In May 2020, he jointly led work, again published in Nature Medicine, to develop an early warning system for age-related macular degeneration (AMD), by far the commonest cause of blindness in many countries. In October 2019, he was included on the Evening Standard Progress1000 list of most influential Londoners and in 2020 he was listed on the “The Power List” by The Ophthalmologist magazine, a ranking of the Top 100 most influential people in the world of ophthalmology.https://www.linkedin.com/in/pearse-keane-27074a6

What is pain? Where does it start and end? In the mind, nerve endings, or somewhere else? In this final episode of the first season of Invent: Health from TTP, we'll be exploring the many and varied facets of this most essential of human experiences. Speaking with specialists in the fields of psychology and neuroscience, we'll find out what is being done to measure pain, to mitigate its severity and what the future of pain relief looks like, to see if people involved in healthcare and drug delivery should be giving pain more attention in their work.Find out more on this week's episode of Invent: Health from TTP.This Week's GuestsDan Lock is a consultant in psychology and human factors at TTP. A psychologist by background, Dan leads on understanding the users of our products, exploring their motivations and figuring out those design features that translate into long-term adherence to medication.https://www.linkedin.com/in/danlock/Dr. Hannah Claridge is a Neural Interfaces specialist here at TTP who, after a Master's degree in Physics and a Ph.D. in Clinical Neurosciences from the University of Oxford, now specialises in neurotechnology and biosensing, developing clinical technologies for some of the world's largest Med Tech companies and ambitious startups.https://www.linkedin.com/in/hannah-claridgeDr. David Cottenden is a consultant here at TTP. He holds a Masters Degree in Mathematics from Cambridge University and a PHD in biomechanics from UCL. David's work has encompassed everything from developing medical devices to exploring and mapping pain in drug delivery.https://www.linkedin.com/in/david-cottenden-7661b64b/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

Healthcare's coming home, it's coming home… Or is it? Recent years - and increasingly since COVID 19 - have seen healthcare moving into the home, with patients using more digital products to track their health from the comfort of their sofas. But why? What was the initial trigger for this? What are the risks and benefits? Will this see a dystopian world where only the rich see doctors in person or a complete democratisation of convenient healthcare? In this episode of Invent Health we break down healthcare in the home to see the benefits and blockers in the now and in the future.Find out on this week's episode of Invent: Health from TTP.This Week's GuestsClayton Poppe is the CTO of Diality. From their base in California, Diality is redefining home dialysis, enabling patients in Kidney failure to undergo hemodialysis, in their own home. An engineer  and technical management professional by background, Calyton specializes in new product and technology development and process scale-up.https://www.linkedin.com/in/claytonpoppe/Alex Gilbert has worked within the Digital Health Industry for a number of years alongside healthcare, pharmaceutical and tech organisations. He joined Huma (previously called Medopad) as one of their first employees and currently manages global Life Sciences Partnerships and Digital Medicine development. Huma is one of the UK's highest-growth digital health companies, having raised over 50 Million in funding, whilst partnering with Apple and Tencent. His passion is the use of technology to empower and engage the patient to take control of their care.https://www.linkedin.com/in/alexgilberthuma/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

Surgical robotics are all the rage right now. Attracting huge investment from the biggest names in healthcare devices, the use of robots in surgery has the potential to change the industry in some really profound and exciting ways. However, some have criticised their implementation as an unnecessary expense when humans can perform these tasks just as well. This episode of Invent: Health will see our guests debate the efficacy and effectiveness of surgical robotics, seeing whether it's the future of surgery, or just tech for tech's sake. We'll also look to the future to see how big an impact this is going to have in the coming years.Find out on this week's episode of Invent: Health from TTP.This Week's GuestsDr. Paul Galluzzo has worked at TTP for the past 18 years. Before that, he did a PhD in mechanical engineering at Cambridge included building a robot to play the cello very accurately. Since then, he has worked across a wide range of markets and products at TTP, from gardening tools to DNA sequencing to inkjet.  Inkjet was a fruitful pathway into ultrasound imaging, and ultrasound was in turn a gateway into medical technology about ten years ago. He now specialises mostly in the technology enablers in med-tech: navigation, visualisation, critical structure detection, energy delivery, implants, and of course surgical robotics.https://www.linkedin.com/in/paul-galluzzo-1132113/Dr. Dwight Meglan, whose doctorate is in Mechanical Engineering, has worked on complex medical systems for more than 25 years as part of teams at a number of high technology medical startups as well as major medical device companies. As a result, he has worked on eight commercial surgical robots (NOTES, abdominal/thoracic, endovascular, electrophysiology, cardiac, gastrointestinal), multiple unique medical devices, as well as numerous surgical simulators combining real-time computational physics, VR/AR displays and custom haptics interfaces. His early work was in orthopedic biomechanics at Ohio State with a postdoc at Mayo Clinic where he turned down a tenure track position so he could stay involved in hands-on work.https://www.linkedin.com/in/dmeglan/Dr. Mark Slack is the Chief Medical Officer and one of the co-founders of CMR Surgical, a global surgical robotics company that has developed Versius, a next-generation robotic system used to perform keyhole surgery. Today, Versius is being used in routine clinical practice to deliver high quality surgical care to patients around the world. Mark qualified in Medicine from the University of the Witwatersrand, Johannesburg and completed his postgraduate training in Obstetrics & Gynaecology at the University of Cape Town. During this time he was awarded the prestigious Daubenton Gold Medal from the College of Medicine of South Africa. Mark established the Urogynaecology service at Addenbrooke's Hospital which has recognised accreditation by the British Society of Urogynaecology. He is also on the Editorial Board for the journal 'BMJ Surgery, Innovation and Health Technology'. He is a Fellow of the Royal College of Obstetricians and Gynaecologists and an official spokesperson for the college.https://www.linkedin.com/in/mark-slack-3b8a2139/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

Humans are designed to make decisions in the now, not ones in the abstract long term. That's why ‘cathedral thinking' comes so hard to us - so it's understandable that making healthcare more sustainable is hard when its primary function is first and foremost to save lives today, not the planet tomorrow. It's easy to say you want to be more sustainable but when you're dealing with people's lives, does sustainability go out of the window? So what can we actually do? This episode of Invent: Health sees us explore the difficulties and challenges as healthcare industries try to become more sustainable.Find out on this week's episode of Invent: Health from TTP.This Week's GuestsDr Michael Spiro is an anaesthetic and intensive care consultant at a London NHS teaching hospital. He has research interests in resource utilisation, enhanced recovery, innovation and sustainability in health care.https://www.linkedin.com/in/mike-spiro-b40a3289/Dr Seema Gandhi is a professor in the department of anaesthesia and the medical director of sustainability at University of California, San Francisco Health System. Trained in India/ UK and the US, she has a global perspective of the practice of medicine and her research focused on decreasing carbon emissions and waste from healthcare. Dr Gandhi is involved in many initiatives focused on Reduction of single use devices, energy consumption and increasing  sustainability focused education among healthcare providers.https://anesthesia.ucsf.edu/people/seema-gandhiMaria Koijck is a Dutch artist and activist based in Groningen. Her artistic practise has focused on waste for many years. Whether it's sculptures made from plastic bottles or tackling the issue of beachside pollution in countries as far afield as Sierra Leone, Maria's work consistently takes aim at the unsustainable use of plastics while simultaneously opening up questions on how we might solve it. https://www.mariakoijck.com/https://www.youtube.com/watch?v=w28M7wjIr6EThe Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://ttp.com/invent

Of all the senses, sight is perhaps our most important. The eye is one of the most incredible organs in nature: it enables us to perceive the world around us, understanding our world through images. And yet we only see a small aspect of reality. But the eye is important beyond just sight. It can also provide a window into our overall health, showing indicators for other things like alzeihmers and blood pressure. In this episode of Invent Health we breakdown the world of modern eyecare to find the ways that tech is improving our collective vision. We'll hear about preventative procedures, cures to restore sight and the global discrepancies in treatment, alongside really getting to grips with what the future of healthcare looks like for perhaps our most vital organs.Find out on this week's episode of Invent: Health from TTP.This Week's GuestsDr Jose-Alain Sahel is currently the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Eye Center, and the Eye and Ear Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute in Paris, a research centre associated with the one of the oldest eye hospitals in Europe. He is a pioneer in the field of artificial retina and eye regenerative therapies and a member of the French Academy of Sciences.https://en.wikipedia.org/wiki/Jos%C3%A9-Alain_SahelPearse Keane is a consultant ophthalmologist at Moorfields Eye Hospital, London, and an associate professor at UCL Institute of Ophthalmology. In 2016, he initiated a formal collaboration between Moorfields Eye Hospital and Google DeepMind, with the aim of developing artificial intelligence (AI) algorithms for the earlier detection and treatment of retinal disease. In May 2020, he jointly led work, again published in Nature Medicine, to develop an early warning system for age-related macular degeneration (AMD), by far the commonest cause of blindness in many countries. In October 2019, he was included on the Evening Standard Progress1000 list of most influential Londoners and in 2020 he was listed on the “The Power List” by The Ophthalmologist magazine, a ranking of the Top 100 most influential people in the world of ophthalmology.https://www.linkedin.com/in/pearse-keane-27074a6Catherine Wyman is a mechanical engineer by background who has developed a variety of medical devices and now leads TTP's eyecare team. She and the team focus on addressing unmet needs across ophthalmology, including in the areas we are discussing today.https://www.linkedin.com/in/catherinewyman1The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://ttp.com/invent

Neurotech: what is it? Elon Musk's brain implants that herald a dystopian sci fi future? Or life saving technology which will be able to cure a multitude of injuries: back pain, epilepsy, even paralysis. In this episode of Invent: Health, we take a look at the hype vs the reality in the thrilling field of neurotech, speaking to experts from TTP and beyond to break it down and find out about its history, its current applications and the incredible places it's going in the future.Find out more on this week's episode of Invent: Health from TTP.This Week's GuestsDr. Hannah Claridge is a Neural Interfaces specialist who co leads the neurotechnology team here at TTP. After a Master's degree in Physics and a Ph.D. in Clinical Neurosciences from the University of Oxford, Hannah now specialises in neurotechnology and biosensing, developing clinical technologies for some of the world's largest Med Tech companies and ambitious startups.https://www.linkedin.com/in/hannah-claridgeDr Benjamin Metcalfe is an Assistant Professor at the University of Bath and a co-founder of the Centre for Biosensors, Bioelectronics, and Biodevices – the largest research centre of its type in England. Since starting in this role in 2016 he has published over 40 peer reviewed research papers and co-authored two books on neural interfaces. He holds a number of internal and external posts including as a trustee and non-executive director of both the Institute for Physics and Engineering in Medicine and the charity Designability. His research interests are in the areas of neural interfaces, neural computing, and signal processing.https://researchportal.bath.ac.uk/en/persons/benjamin-metcalfeDr. Chris Dawson co leads the neurotechnology team at TTP with Hannah, working with ambitious clients across this field to develop novel enabling technologies and applying these to medical device development to help bring innovative new products to market. His degree and PhD are in mechanical engineering, and started his career working to develop automation systems to improve development and productivity in life science research, before moving into motorsport and working in the aero department at McLaren to design, develop, and test the aerodynamic elements of their formula one race car. This fast-paced design-develop-deploy environment was great preparation for moving into technology development at TTP, using deep science and engineering expertise to support clients in commercialising their ideas.https://www.linkedin.com/in/chris-dawson-96908268/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://ttp.com/invent

There is now a widespread awareness of the gravity of mental health issues in the general public, and equally in the world of healthcare. But in tandem with its rise we've seen the growth of the so-called "wellness industry", which too often promotes pseudo scientific solutions to the most complex of problems. So how is the health tech industry responding? What are the new frontiers for digital therapeutic care today, especially in the post-pandemic landscape?Find out on this week's episode of Invent: Health from TTPThis Week's GuestsAdonis Bou Chakra is the Co-founder & CPO at Aepsy - designing & building products for better minds. He is a former global Design manager at Sennheiser with an MA Digital Management at Hyper Island.https://www.adonisbc.com/Dr. Rashmi Patel is a MRC UKRI Health Data Research UK Fellow in the Department of Psychosis Studies at the Institute of Psychiatry, Psychology & Neuroscience, King's College London. He has a particular interest in the neurobiology of psychotic disorders and the role of health data research techniques such as extracting data from free text electronic health records (EHRs) using natural language processing to predict clinical outcomes and develop more effective treatment strategies.https://www.kcl.ac.uk/people/dr-rashmi-patel Jordan Abdi is the Strategy and Business Development Lead at Holmusk, a company building the largest Real-World Evidence platform, starting with behavioral health. He is also a World Economic Forum Global Shaper and a Schwarzman Scholar, who is passionate about preventative health. A medical doctor by background, he has close to a decade's experience working in the health technology sector.https://www.linkedin.com/in/jordanabdi/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here.https://ttp.com/invent

Doing what's good for you should seem like second nature, so why is it that we as humans so often don't do things which we know will be effective when it comes to our own health and wellbeing? From difficulties in quitting smoking to the 25% of prescriptions in the UK that are left unfilled, medical non-adherence has profound effects on the health of a population, and it's also one of the trickiest realms for health practitioners to deal with. How do you literally change someone's behaviour if they already know they're doing themselves harm? Find out on this week's episode of Invent: Health from TTP.This Week's GuestsPaul Upham is the Head of Smart Devices at Roche / Genentech and has over 20 years of experience in medical technology and digital health in R&D as well as global marketing and product management roles, including leading the development of the world's first prescription digital therapy for type 2 diabetes, Bluestar, from WellDoc.https://www.linkedin.com/in/paulupham/Dan Lock is a consultant in psychology and human factors at TTP. A psychologist by background, Dan leads on understanding the users of our products, exploring their motivations and figuring out those design features that translate into long-term adherence to medication.https://www.linkedin.com/in/danlock/Dr. Olga Perski is an interdisciplinary scientist working at the intersection of behavioural science and digital health. She is a health psychologist by training and completed her PhD at University College London in 2018, with a thesis on the definition, measurement and promotion of user engagement with digital behaviour change interventions. She is a post-doc in the UCL Tobacco and Alcohol Research Group and a UCL Centre for Behaviour Change Associate. Her work is focused on the development and evaluation of digital interventions for smoking cessation and alcohol reduction.https://www.olgaperski.com/The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients. Find out more about our work here: https://ttp.com/invent

Hello and welcome to Invent: Health, a podcast from technology and product development company TTP.Invent: Health is a podcast about the future of health and technology, hosted by TTP Design and Strategy consultant, Matt Millington. Each week, we'll be joined by the top scientists, designers, business leaders and academics working at the vanguard of this vital industry, to give you a behind-the-scenes look at the world of health tech.See you soon!